Navigation Links
Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
Date:10/25/2007

Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients. For many years, corticosteroids have represented the cornerstone of therapy for induction of remission in Inflammatory Bowel Disease (IBD); however, the side-effects emerging with long-term use exceeded the clinical benefits. Recently, Infliximab (IFX) has become an alternative choice in the treatment strategies for CD and UC. Some safety issues are associated with IFX use, mostly related to the development of adverse events (e.g. opportunistic infections, autoimmune disorders and infusion reactions). Major concerns are related to the reactivation of latent tuberculosis and development of malignancy, even if there is no clear evidence the use of IFX increases the incidence of solid cancers. The research published on issue 39 of World Journal of Gastroenterology and led by Renato Caviglia at University Campus Biomedico in Italy aimed to retrospectively evaluate the safety and efficacy of long-term therapy with IFX, reviewing the medical charts of 41 IBD patients who received, after a loading dose of 3 IFX infusions, scheduled retreatment every 8 weeks as maintenance protocol.

Results of this retrospective study confirm current data on the efficacy of IFX in inducing a rapid clinical response in CD and UC, and support the finding, emerging from uncontrolled study data, of prolonged clinical efficacy in maintaining long-lasting remission beyond 1 year of treatment. The steroid-sparing effect of IFX was another important finding emerging from our study, which confirmed the efficacy of a scheduled treatment regimen in avoiding the well-known morbidity associated with long-term corticosteroid therapy. Interestingly, long-term IFX therapy in IBD has been demonstrated to potentially modify the course of the disease. Indeed, 9 out of the 29 CD and 4 out of the 9 UC patients, who discontinued IFX scheduled treatment, were still relapse-free after a median of 16 (range, 5-30) and 6.5 (range, 4-16) months since the last IFX infusion, respectively.

A note of caution is mandatory when considering the possible risk of malignancy associated with the use of anti-TNF-alpha therapy. Further studies on larger scales are needed to further clarify these important aspects.


'/>"/>

Contact: You-De Chang
y.d.chang@wjgnet.com
0086-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Rescheduled: Aerial Mosquito Treatment for Philadelphia
2. First Keyhole Heart Valve Surgery Scheduled in Britain
3. Advances in Treatment of Cataracts
4. Recommendations for Treatment of Blood Pressue
5. Thyroid hormone treatment hastens recovery after cardiac surgery
6. Feeding channel created by malaria parasite - a new target for malaria treatments
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, U.S. Senate Republicans revealed ... repeal and replace the Affordable Care Act (ACA). Like the bill narrowly passed ... Medicaid, a public health insurance program for low-income children, pregnant women, parents of ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection ... denied entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger ... six years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... and two new videos highlight the importance of correctly using a meat thermometer. ... who has done extensive research on consumer food safety habits. Dr. Bruhn explains ...
(Date:6/23/2017)... ... ... PureLife Dental is pleased to announce that California Dental Association (CDA) has ... the amalgam separator endorsement, all CDA members may purchase an ECO II amalgam separator ... This partnership between PureLife and CDA is especially timely as it coincides with the ...
(Date:6/23/2017)... ... 23, 2017 , ... The Katyl Agency, a locally owned ... business owners in and around Lackawanna County, is joining Meals On Wheels of ... , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to seniors ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology: